Skip to content
etf.net

GNMX vs XBI

Corgi Genomics & Precision Medicine ETF

GNMXCCboe

State Street SPDR S&P Biotech ETF

XBIANYSE Arca

Overlap

Expense ratio

Same figure. Both funds show the same value, so neither comes out ahead.

GNMX0.35%XBI0.35%

Avg volume · 30D

XBI 5004.0×the volume

GNMX1.79KXBI8.95M

GNMX vs XBI Performance

Jul 31, 2026 – Oct 30, 2026

+28.1%GNMX+6.1%XBI

Jul 31, 2026 to Oct 30, 2026. GNMX +28.1%. XBI +6.1%. Use the arrow keys to read each point.0%20%Jul 2026Sep 2026Oct 2026
Expense ratio
GNMX 0.35%
XBI 0.35%
Fund size
GNMX $1M
XBI $10.8B
1Y total return
GNMX No data
XBI +39.0%
Yield (12M)
GNMX No data
XBI 0.35%
Holdings
GNMX 58
XBI 164
Avg volume (30D)
GNMX 1.79K sh
XBI 8.95M sh, better
NAV per share
GNMX $38.06
XBI $157.82
52W range

ETF.net Grade

GNMX: Cost 81, Risk 71, Mission not scored, Tradability 17, Holdings 49, Durability 0. XBI: Cost 81, Risk 47, Mission 85, Tradability 99, Holdings 88, Durability 89.
Pillar letters and Scores for GNMX, XBI, with each pillar’s weight
PillarGNMXXBI
Cost30% weightA81A81
Mission25% weightNot scoredA85
Risk15% weightA71HigherC47
Tradability15% weightF17A99Higher
Holdings10% weightC49A88Higher
Durability5% weightF0A89Higher

Rank among Biotech & Genomics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. GNMX and XBI are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds
See all 17 ›

XBI ranks 1st and GNMX 11th of 17 funds in the Biotech & Genomics Category.

  1. Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
  2. Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
  3. Rank 10CIBRNiShares Neuroscience and Healthcare ETFScore 43
  4. Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40
  5. Rank 11CWDNAWisdomTree BioRevolution FundScore 40

Our read on each fund

ETF.net Research

GNMXCCorgi Genomics & Precision Medicine ETF

XBIAState Street SPDR S&P Biotech ETF

In short

GNMX No data

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

GNMX No data

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

GNMX No data

  • XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
  • 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
  • Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
  • A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

GNMX No data

  • XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
  • Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
  • One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full GNMX profile⁠

Full XBI profile⁠

GNMX vs XBI Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

GNMX vs XBI Cost

Same expense ratio

$7,126

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • GNMX 0.35%

    $7,126

  • XBI 0.35%

    $7,126

$10,000
30 years

Cost over time

  • GNMX 0.35%
  • XBI 0.35%
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K051015202530GNMX $7,126XBI $7,126

Year by year

YearGNMXXBI
10$634$634
20$2,454$2,454
30$7,126$7,126

Expense ratio

  • 0.35%GNMX
  • 0.35%XBI
  • Middle half of Biotech & Genomics funds
  • Median 0.47%

GNMX 3rd cheapest of 17 funds

XBI 3rd cheapest of 17 funds

GNMX vs XBI Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
GNMX No data
XBI 0.35%
Payout (12M)
GNMX None
XBI $0.54
Last payment
GNMX No data
XBI $0.14
Ex-dividend
GNMX No data
XBI Jun 22, 2026
Paid on
GNMX No data
XBI Jun 24, 2026
Frequency
GNMX No data
XBI Twice a year

Distribution history

Per share, 2017 to 2026, same scale for both

GNMXAll GNMX payments⁠

No distribution history available.

XBITwice a year · 24 paymentsAll XBI payments⁠
One bar per payment. 24 payments from 2017 to 2026 YTD. Mar 17, 2017 $0.02; Jun 16, 2017 $0.11; Sep 15, 2017 $0.04; Dec 15, 2017 $0.04; Mar 16, 2018 $0.06; Jun 15, 2018 $0.06; Sep 21, 2018 $0.07; Dec 21, 2018 $0.01; Sep 20, 2019 $0.0032; Dec 20, 2019 $0.00086; Jun 22, 2020 $0.02; Sep 21, 2020 $0.09; Dec 21, 2020 $0.18; Mar 22, 2021 $0.04; Jun 20, 2023 $0.0026; Dec 18, 2023 $0.01; Jun 24, 2024 $0.11; Sep 23, 2024 $0.02; Dec 23, 2024 $0.0027; Mar 24, 2025 $0.0053; Jun 23, 2025 $0.0073; Sep 22, 2025 $0.03; Dec 22, 2025 $0.41; Jun 22, 2026 $0.14. Use the arrow keys to read each point.$0$0.252017202020232026YTD

GNMX vs XBI Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years
GNMX No dataXBI 24.8%
Return per unit of riskSharpe ratio, 3 years
GNMX No dataXBI 1.11
Worst fallMax drawdown, 5 years
GNMX No dataXBI −53.2%
Market sensitivityBeta, 5 years
GNMX 2.27XBI 1.10

GNMX and XBI in the news

All news⁠

Popular comparisons

  • GNMXCvsIBBQA

    Corgi Genomics & Precision Medicine ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.35% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • XBIAvsIBBQA

    State Street SPDR S&P Biotech ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.35% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • GNMXCvsIBBA

    Corgi Genomics & Precision Medicine ETF · iShares Biotechnology ETF

    Expense ratio
    0.35% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • XBIAvsIBBA

    State Street SPDR S&P Biotech ETF · iShares Biotechnology ETF

    Expense ratio
    0.35% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • GNMXCvsBBPA

    Corgi Genomics & Precision Medicine ETF · Virtus Biotech ETF

    Expense ratio
    0.35% · 0.34%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • XBIAvsBBPA

    State Street SPDR S&P Biotech ETF · Virtus Biotech ETF

    Expense ratio
    0.35% · 0.34%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.